Zinzino AB (publ)

Year-end Report 2020 - Seite 2

• Total revenue increased by 48% to SEK 1,138.6 (770.6) million           
• Gross profit amounted to SEK 348.6 (232.3) million, of which items affecting comparability regarding reporting of sales commissions amounted to SEK 22.2 million. Gross profit margin amounted to 30.6% (30.1%)           
• EBITDA amounted to SEK 108.5 (33.5) million and the EBITDA margin to 9.5% (4.4%)           
• Adjusted EBITDA amounted to SEK 86.3 (33.5) million and the adjusted EBITDA margin to 7.6% (4,4%)           
• Cash flow from operating activities totalled SEK 97,3 (71,3) million           
• Liquid assets on the balance sheet date were SEK 143.2 (76.8) million

For more information:
Dag Bergheim Pettersen CEO Zinzino [phone], zinzino.com

Pictures for publication free of charge:
Marcus Tollbom [phone], [e-mail]

Certified Adviser: Erik Penser Bank Aktiebolag, [phone], email: [e-mail]

Zinzino AB (publ) is obliged to publish this information in compliance with current EU regulations governing market abuse. The information was provided by the above contact person for publication at 08.00 the 26^th of February 2021.

Zinzino AB (publ.) is a global Direct Sales company that markets and sells test-based nutrition, skincare and life-style products. Zinzino owns the research unit BioActive Foods AS and production unit Faun Pharma AS. Zinzino is based in Gothenburg, with additional offices in Finland, Latvia, Norway, USA, Australia, Hong Kong and Malaysia. Zinzino is a public company and its shares are listed on Nasdaq First North Premier Growth Market.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/zinzino/r/zinzino-ab--publ--year-end-report-2020,c3296271

The following files are available for download:

https://mb.cision.com/Main/10976/3296271/1379281.pdf	Interim report Q4 2020 (PDF)
https://mb.cision.com/Public/10976/3296271/93d5cbe08441ca6a.pdf	Press release (PDF)